Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Toripalimab in Renal Cell Carcinoma: NCT06221774 Clinical Landscape Report 2026
16 October 2026
NCT06221774 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Triptorelin Pamoate in Premenopausal breast cancer: NCT06225284 Clinical Landscape Report 2026
16 October 2026
NCT06225284 clinical landscape for Premenopausal breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amiloride Hydrochloride in HER2-Low Breast Carcinoma: NCT06224673 Clinical Landscape Report 2026
16 October 2026
NCT06224673 clinical landscape for HER2-Low Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lidocaine/Prilocaine in Pain: NCT06223659 Clinical Landscape Report 2026
16 October 2026
NCT06223659 clinical landscape for Pain: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CTS-2190 in Triple Negative Breast Cancer: NCT06224387 Clinical Landscape Report 2026
16 October 2026
NCT06224387 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YY-201 (Shanghai Yuyao) in Acute Myeloid Leukemia: NCT06225856 Clinical Landscape Report 2026
16 October 2026
NCT06225856 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tetravalent influenza vaccine(Split, inactivated)(Sanofi) in Triple Negative Breast Cancer: NCT06229392 Clinical Landscape Report 2026
16 October 2026
NCT06229392 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pafolacianine in Metastatic osteosarcoma: NCT06235125 Clinical Landscape Report 2026
16 October 2026
NCT06235125 clinical landscape for Metastatic osteosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Anti-CD19 CAR-T cells(University of Utah) in Acute Lymphoblastic Leukemia: NCT06227026 Clinical Landscape Report 2026
16 October 2026
NCT06227026 clinical landscape for Acute Lymphoblastic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Hydroxychloroquine Sulfate in Lung Cancer: NCT06229340 Clinical Landscape Report 2026
16 October 2026
NCT06229340 clinical landscape for Lung Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Advanced Triple-Negative Breast Carcinoma: NCT06229067 Clinical Landscape Report 2026
16 October 2026
NCT06229067 clinical landscape for Advanced Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Clindamycin Hydrochloride in Melanoma, Cutaneous Malignant: ACTRN12624000076572 Clinical Landscape Report 2026
16 October 2026
ACTRN12624000076572 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white…